-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$14.25149.13% Upside
Terns Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Terns Pharmaceuticals, Inc.?
Terns Pharmaceuticals, Inc. has been rated by research analysts at BMO Capital, Mizuho Securities, H.C. Wainwright, Goldman Sachs in the past 90 days.